Overview

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
Investigators conduct the clinical trial to further explore the efficacy and safety of Fruquintinib combined with S-1 in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital